C90.20 ICD-10-CM Code: Extramedullary plasmacytoma not having achieved remission
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C90.20
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceExtramedullary plasmacytoma not having achieved remission
Extramedullary plasmacytoma, a tumor of plasma cells that occurs outside the bone marrow, that has not responded to treatment.

Buddy Insight
Extramedullary plasmacytoma is a solitary tumor of neoplastic plasma cells occurring outside the bone marrow, most commonly in the upper respiratory tract including the nasopharynx, paranasal sinuses, and oropharynx.
CMS-HCC V28
MappedHCC 19
RAF 1.798
CMS-HCC V24
MappedHCC 9
RAF 1.024
ACA/HHS
MappedHCC 9
Varies by metal level
ESRD/PACE
MappedHCC 9
RAF 0.181
RXHCC
MappedHCC 16
RAF 14.205
Code Book Path
Inclusion Terms
Official- Extramedullary plasmacytoma with failed remission
- Extramedullary plasmacytoma NOS
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C90.20 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C90.20 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C90.20 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C90.20 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C90.20 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C90.20 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C90.20 an HCC code?
Yes. C90.20 (Extramedullary plasmacytoma not having achieved remission) maps to Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers under the CMS-HCC V28 risk adjustment model (and Lung and Other Severe Cancers under V24), with a community non-dual aged RAF of 1.798. It is billable for payment year 2026.
Coder answer: C90.20 is billable and maps to V28 HCC 19, Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C90.20
- Description
- Extramedullary plasmacytoma not having achieved remission
- HCC (V28)
- HCC 19 — Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers
- RAF
- 1.798
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work C90.20 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for C90.20
For C90.20 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C90.20 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C90.20 is the ICD-10-CM diagnosis code for extramedullary plasmacytoma not having achieved remission. Extramedullary plasmacytoma, a tumor of plasma cells that occurs outside the bone marrow, that has not responded to treatment. C90.20 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C90.20 maps to Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers (HCC 19) with a community, non-dual, aged base RAF weight of 1.798. Under the older CMS-HCC V24 model, C90.20 maps to Lung and Other Severe Cancers (HCC 9) with a community, non-dual, aged base RAF weight of 1.024. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Extramedullary plasmacytoma occurs in soft tissues outside bone marrow; verify location is documented. Because C90.20 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C90.20 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Extramedullary plasmacytoma occurs in soft tissues outside bone marrow; verify location is documented
- •Fifth character '0' indicates no remission; document the site of the tumor for complete coding
Clinical Significance
Extramedullary plasmacytoma is a solitary tumor of neoplastic plasma cells occurring outside the bone marrow, most commonly in the upper respiratory tract including the nasopharynx, paranasal sinuses, and oropharynx. Unlike multiple myeloma, it is typically a localized disease amenable to radiation therapy. Non-remission status indicates the tumor persists or has progressed despite treatment.
Documentation Requirements
- ✓Documentation must include tissue biopsy confirming a monoclonal plasma cell tumor outside the bone marrow.
- ✓The specific extramedullary site must be documented.
- ✓Imaging confirming absence of additional lesions, bone marrow biopsy excluding myeloma, serum and urine protein studies, treatment approach (typically radiation), and non-remission status are required.
Commonly Confused Codes
- •C90.21 (extramedullary plasmacytoma in remission) requires documented remission.
- •C90.30 (solitary plasmacytoma) refers to bone plasmacytoma, which is within the skeletal system.
- •C90.00 (multiple myeloma) involves systemic disease with bone marrow infiltration.
- •D47.Z9 (neoplasm of uncertain behavior of lymphoid tissue) is for borderline lesions.

